Zhao D, Gao J. Allogenic CD19 CAR NK Cells Therapy in Refractory Systemic Lupus Erythematosus: An Open-label, Single Arm, Prospective and Interventional Clinical Trial [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9...
2024年美国风湿病学会(ACR)年会汇聚了众多风湿病领域的前沿研究成果,系统性红斑狼疮(SLE)相关研究是其中的重要部分。这些研究涵盖新疗法、现有疗法优化及疾病管理策略改进等方面,为SLE患者的治疗和管理带来新希望,以下为部分治疗相关重点研...
参考文献：[1] Zou H, Wan W, Xue Y, et al. Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). [2] Guillermo Sánchez-Rodríguez et,al Pathogenic Role of...
[10] Abstract 0098. Washington University & Karolinska Institutet Sweden [11] Megan Clowse. et al. Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efricacy and Safety Results of a Phase 3 Trial. 2024 ACR. Late-Breaking Abstracts: L16. [12...
原文:Galloway J, Avouac J, Burmester G, et al. Maintained Improvement of Disease Activity and Patient-reported Outcomes (PROs) with Filgotinib in Patients with Rheumatoid Arthritis (RA) in the Real World: Up to 2-year Interim Data from FILOSOPHY [abstract]. Arthritis Rheumatol. 2024; 76 (...
Monday, February 5, 2024 Withdrawal deadline: Monday, February 19, 2024 点此提交摘要>>>Submit Abstract>>> Formatting Your Abstract In accordance with HIPAA regulations, patient confidentiality must be protected. Names, dates of scans, birth dates, ages, medical record numbers, zip codes and iden...
5、ABBV-599(Elsubrutinib与乌帕替尼联合用药):长期治疗的新选择最后,让我们看看ABBV-599(Elsubrutinib与乌帕替尼联合用药)的研究(Abstract Number:2577)。这项长期扩展研究至104周的结果表明,ABBV-599高剂量或乌帕替尼单药治疗在中重度活动性SLE患者中可维持或进一步实现疾病活动度降低、减少病情复发并降低糖皮质...
[1] Zou H, Wan W, Xue Y, et al. Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). [2] Guillermo Sánchez-Rodríguez et,al Pathogenic Role of IL-17 ...
[2]https://acrabstracts.org/abstract/elevated-line-1-expression-in-sle-keratinocytes-leads-to-line-1-reverse-tranase-dependent-type-i-interferon-responses.(2023.11.12) [3]https://acrabstracts.org/abstract/involvement-of-type-i-interferon-responsive-myeloid-cells-in-renal-inflammation-in-a-lupus-...
Session date and time:Saturday, November 16, 2024, 10:30 AM - 12:30 PM Abstract ID:1857761 Title:IRAK4 Degrader GS-6791 Inhibits TLR and IL-1R-Driven Inflammatory Signaling, and Ameliorates Disease in a Preclinical Arthritis Model Prese...